Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585979 | 0.80 | NPSR1 (0.44) | NPC1RAB9AALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL5381977 | 0.79 | ALDH1A1 (0.48) | NPC1RAB9AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL4762222 | 0.75 | CYP3A4 (0.47) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1943555 | 0.75 | NPC1 (0.40) | NPC1RAB9AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL5373150 | 0.75 | GLS (0.45) | NPC1RAB9AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL25523259 | 0.73 | ALDH1A1 (0.54) | NPC1RAB9AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL2380294 | 0.73 | NPC1 (0.47) | NPC1RAB9AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL2427334 | 0.73 | RAB9A (0.60) | NPC1RAB9AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL1943940 | 0.70 | KMT2A (0.57) | NPC1RAB9AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL19778 | 0.70 | NPSR1 (0.70) | NPC1RAB9AALDH1A1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-7906645-B2 | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | CCR2, CCR3, CXCR2 | NPC1 1260/4885RAB9A 3914/4885ALDH1A1 3238/4885 |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | CCR2, CCR3, CXCR2 | NPC1 1658/4885RAB9A 4068/4885ALDH1A1 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.